GlassScriptPhysician profile
Asheema Bacchus
NPI 1699209296
$2,939.60
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $454 · 2021: $1,095 · 2022: $882 · 2023: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $509.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $650.44 | 2020-2023 | Jardiance |
| Glaxosmithkline, LLC. | $382.09 | 2020-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $247.09 | 2020-2023 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.72 | 2020-2022 | |
| Novo Nordisk INC | $239.90 | 2020-2023 | Wegovy |
| Abbvie INC. | $173.30 | 2021-2023 | Dalvance, Qulipta |
| Amgen INC. | $169.66 | 2021-2023 | Otezla, Repatha |
| Pfizer INC. | $168.67 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $117.03 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $87.00 | 2022-2023 | Spravato |
| Abbott Laboratories | $80.34 | 2021-2023 | Freestyle Libre 2, Proclaim |
| Novartis Pharmaceuticals Corporation | $54.39 | 2022-2023 | |
| Dexcom, INC. | $48.61 | 2020-2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $45.77 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $45.08 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $31.01 | 2023 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $27.96 | 2020 | |
| Daiichi Sankyo INC. | $19.82 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.68 | 2023 | Quviviq |
| Cranial Technologies, INC | $17.87 | 2022 | |
| Eisai INC. | $15.10 | 2021 | |
| Phadia US INC. | $14.49 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.09 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.89 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asheema Bacchus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.